Legend Biotech (LEGN) Gross Margin (2019 - 2025)
Legend Biotech filings provide 7 years of Gross Margin readings, the most recent being 79.04% for Q4 2025.
- On a quarterly basis, Gross Margin rose 526.0% to 79.04% in Q4 2025 year-over-year; TTM through Dec 2025 was 79.99%, a 350.0% increase, with the full-year FY2025 number at 80.0%, up 351.0% from a year prior.
- Gross Margin hit 79.04% in Q4 2025 for Legend Biotech, down from 80.68% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 83.88% in Q2 2024 to a low of 97963.15% in Q1 2021.
- Median Gross Margin over the past 5 years was 64.2% (2023), compared with a mean of 4857.51%.
- Biggest five-year swings in Gross Margin: crashed -9800646bps in 2021 and later skyrocketed 9802058bps in 2022.
- Legend Biotech's Gross Margin stood at 35.43% in 2021, then surged by 118bps to 6.55% in 2022, then soared by 780bps to 57.62% in 2023, then increased by 28bps to 73.78% in 2024, then grew by 7bps to 79.04% in 2025.
- The last three reported values for Gross Margin were 79.04% (Q4 2025), 80.68% (Q3 2025), and 81.16% (Q2 2025) per Business Quant data.